ANTIMICROBIAL AGENTS

Determination of the antibacterial efficacy of several antiseptics tested on skin by an ‘ex-vivo’ test

SYNDIE MESSAGER, P. A. GODDARD*, P. W. DETTMAR* and J-Y. MAILLARD

Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF and *Reckitt and Colman Products, Dansom Lane, Hull HU8 7DS

There are many skin antiseptics commercially available. Although their antibacterial activity has often been well studied [1], their potential effectiveness on skin remains poorly documented. To date, in-vivo protocols designed for the testing of the antimicrobial efficacy of antiseptics cannot use, for ethical reasons, pathogenic bacteria or new formulations whose toxicity in human subjects is unknown. An ‘ex-vivo’ test was recently developed to overcome these problems. Freshly excised human skin from abdominal or breast reduction was placed in a diffusion cell containing a maintenance medium in the recipient compartment. A bacterial inoculum was then applied to the stratum corneum and, after a drying step, antiseptic formulations were evaluated for their antimicrobial activity. Several micro-organisms were investigated: – Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), Enterococcus faecalis, vancomycin-resistant Ent. faecium (VRE), S. epidermidis, Pseudomonas aeruginosa and Escherichia coli – with several biocides – para-chloro-meta-xylanol (PCMX, active compound of Dettol), povidone iodine, triclosan (in isopropanol) and chlorhexidine. Results from the ex-vivo test were compared with results obtained in suspension and glass-carrier tests. The bactericidal activity of the biocides depended upon the test performed and results were generally significantly different from one method to the other. All biocides tested in the suspension test achieved >4 log10 reduction in viable bacterial concentrations, apart from povidone iodine tested against Ent. faecalis and VRE. The antibacterial activity of biocides tested in the glass-carrier test was significantly lower than in the suspension test, with the exception of triclosan in isopropanol, which was as effective in both suspension and glass-carrier test. In the ex-vivo test, triclosan in isopropanol achieved a log10 reduction in viable bacterial concentration of 1.105–1.771 (with the exception of P. aeruginosa with 0.758 log10 reduction). PCMX, povidone iodine and chlorhexidine achieved log10 reductions in viable bacterial concentration of 0.303–0.901. Chlorhexidine tested against P. aeruginosa produced a 1.94 log10 reduction in concentration. These results confirm previous observations about the need for testing the antimicrobial activity of antiseptics on skin surface to determine their in-situ efficacy and encourage further the use of the ex-vivo protocol.

Introduction

The transfer of pathogenic bacteria via the hands of staff in health care centres is often the source of outbreaks of nosocomial infections. Hand-washing with a skin disinfectant is an important practice for reducing the risk of infection but, as has already been shown among hospital staff, hands are washed too seldom, the antiseptics used are often chosen randomly and hand-washing technique is poor [2]. Furthermore, frequent use of antiseptics and some scrubbing techniques can be the cause of skin irritation or allergies, which might explain in part the low frequency of hand-washing [3].

There are many skin antiseptics commercially available. However, the effectiveness of the products is usually investigated by in-vitro techniques, as their activity on human skin is difficult to assess. Indeed,
only in-vivo trials can evaluate the efficacy of antiseptic products directly on human skin, thus
retranscribing the ‘in-use’ practice. However, for
ethical reasons, only non-pathogenic bacteria and
products whose safety for human subjects is known
can be tested in these in-situ studies. Furthermore, most
studies performed in vivo with volunteers have shown
some important variability in results. This is often due
to the hand-washing techniques, which can vary
significantly among subjects, rather than to the
antiseptic tested [4].

There has been a search for a substitute for both in-vitro
and in-vivo protocols because of the deficiencies and
limitations of these tests; i.e., variability in results with
clinical studies as well as limitation in micro-organisms
and antiseptics to be tested. Furthermore, results from
in-vitro techniques have to be taken into account
cautiously as they have been shown to overestimate
the antibacterial efficacy of biocides, as in the suspen-
sion test [5] or can sometimes be difficult to interpret
because of the significant loss of bacterial cells caused
only by pre-treatment, as in the glass-carrier test [5].

The aim of this study was to investigate the anti-
microbial properties of several biocides commonly used
in formulations with antiseptic properties against several
pathogenic micro-organisms, including some antibiotic-
resistant strains, by three different methods: a suspen-
sion test, a glass-carrier test and the ex-vivo protocol.

Materials and methods

Test organisms

*Pseudomonas aeruginosa* (NCIMB 10421), *Staphylo-
coccus epidermidis* (P69; Cardiff University), *S. aureus*
Oxford (NCTC 6571), *Escherichia coli* K12 (NCTC
10538), *Enterococcus faecalis* (Q 33; Cardiff Univer-
sity), methicillin-resistant *S. aureus* (MRSA) (9543;
Cardiff University) and vancomycin-resistant *Ent.
faecium* (Z31901; VRE; University of Wales, College
of Medicine) were grown overnight in Tryptone Soya
Broth (TSB; Oxoid) at 37.1 ± 0.45°C in a water bath
(Gallenkamp) with constant agitation (90 rpm). Stock
cultures were made on Tryptone Soya Agar (TSA;
Oxoid) plates and slopes, stored at 4°C and renewed
once a week.

Viable bacterial concentration was determined by the
drop counting method [5]. Briefly, a 0.1-ml sample was
serially diluted in sterile phosphate-buffered saline (PBS;
Sigma) and 10-μl drops were plated on to the surface of
an over-dried TSA plate. After overnight incubation at
36.8 ± 1.5°C, colonies were counted and the viable
bacterial concentration was expressed as cfu/ml.

Chemicals

The antimicrobial activity of the following biocides
was investigated: PCMX 0.24% w/v (Dettol diluted to
5%; Reckitt & Colman Hall, E. York), povodine iodine
2% w/v (Pov; Sigma), chlorhexidine 2% w/v (CHX;
Sigma), triclosan 0.5% w/v (TRI; Ciba Specialty
Chemicals) in isopropanol (Sigma) 70% v/v and
isopropanol (Sigma) 70% v/v. These solutions were
made fresh in sterile ultrapure water (Nanopure, Barnstead) and autoclaved according to the British
Pharmacopeia procedure [6].

Neutralisers

Neutralising solutions used to quench the activity of
disinfectants were based on the British Standard EN
1499 [7] and were made fresh in sterile ultrapure water
(Nanopure); concentrations are given /L of TSB
(Oxoid) and were as follows. Pov 2% was neutralised
by ‘neutraliser A’: polysorbate 80 (Sigma) 30 g/L,
lecithin from eggs (Sigma) 3 g/L, L-histidine (Sigma)
1 g/L, sodium thiosulphate (Fisher) 5 g/L, hypolysed
bovine albumin (Sigma) 1 g/L. TRI 0.5% in isopro-
panol 70% and isopropanol 70% were neutralised by
neutraliser B: polysorbate 80 30 g/L, lecithin from
eggs 3 g/L, L-histidine 1 g/L, sodium thiosulphate
5 g/L. PCMX 0.24% was neutralised by neutraliser C:
polysorbate 80 150 g/L, lecithin from eggs 15 g/L, L-
histidine 5 g/L, sodium thiosulphate 25 g/L. CHX 2% was
neutralised by neutraliser D’: polysorbate 80
30 g/L, lecithin from eggs 3 g/L, L-histidine 1 g/L.

Suspension test

The suspension test protocol was based on the British
Standard EN 1276 [8]. Two controls were performed.
First, to assess the antibacterial activity of the
neutralisers, 1 ml of bacterial inoculum (2 × 10⁸–
2 × 10⁹ cfu/ml) was added to 9 ml of neutraliser and,
after 5-min contact time, a serial dilution was made in
sterile Eppendorf tubes containing PBS and the drop
counting method was used to determined the number
of surviving micro-organisms. Second, to assess the
effectiveness of the neutralisers to quench the ap-
propriate disinfectants, 1 ml of disinfectant was added
to 9 ml of the appropriate neutraliser. After 1-min contact
time, a 9-ml sample was removed and mixed with 1 ml
of a bacterial suspension. This solution was then serially
diluted in Eppendorf tubes containing PBS and bacterial
survival was determined by the drop counting method.

Antibacterial activity of the biocides was determined as
follows: 1 ml of bacterial inoculum (2 × 10⁸–
2 × 10⁹ cfu/ml) was added to 9 ml of a biocide. After
a 1-min contact time, 1 ml of this mixture was added to
9 ml of the appropriate neutraliser. A serial dilution of
this mixture was made in Eppendorf tubes containing
PBS, plated on TSA plates by the drop counting method
and surviving bacteria were counted after overnight
incubation at 36.8 ± 1.5°C. A 1-min contact time was
chosen for the three methods to follow procedures
described in the British Standard EN 1499 [7].
Glass-carrier test

The glass-carrier test was based on a procedure developed elsewhere [9, 10]. Briefly, 20 μl of a bacterial inoculum (2 × 10⁸–2 × 10⁹ cfu/ml) were placed on to the glass surface at the bottom of a sterile bottle (autoclavable glass bottle; Fisher) and dried for 2 h in a laminar flow cabinet (FASTER, BHA 48). A 30-μl sample of biocide was added on to the dried inoculum and, after 1-min contact time, 450 μl of the appropriate neutralising solution were added. Surviving bacteria were resuspended in the neutralising solution and counted by the drop counting method.

The antibacterial activity of the drying process was investigated. After drying in a laminar flow cabinet for 2 h, the dried bacterial inoculum was resuspended in 480 μl of neutraliser or PBS. The number of surviving bacteria was determined by the drop counting method.

Ex-vivo test

The recently developed ex-vivo test [5] was used for testing the antimicrobial activity of biocides against the test micro-organisms on skin. Skin samples were obtained from patients undergoing plastic surgery, mainly breast and abdominal reductions. Donors’ permission was obtained before surgery. Depending on the availability of the skin, tests were performed with either fresh or frozen skin. Fresh samples were stored in Earle’s balanced salts solution (EBSS; Sigma) at 4°C and frozen samples at −20°C until used.

Skin samples of c. 2 cm² were placed on a diffusion cell containing 1 ml of PBS in the recipient compartment to keep the dermis moist (Fig 1). An overnight bacterial culture (20 μl of 2 × 10⁸–2 × 10⁹ cfu/ml) was inoculated on to the stratum corneum and dried for 3 min in a laminar flow cabinet. Biocide (30 μl) was then added to the bacterial inoculum. After a 1-min contact time, 450 μl of the appropriate neutralising solution were added on to the skin sample. Surviving bacteria were resuspended in the neutraliser and counted by the drop counting method. As human skin is not easily obtainable, skin samples were sometimes used twice. Before re-use, the skin surface was rinsed three times in sterile PBS.

Information about the donor, sex, age, sample origin, frozen or fresh skin, first or second use, as well as their permission were recorded and taken into account for the statistical analyses of the results.

Two controls were performed with the ex-vivo protocol. Resident flora was investigated by rinsing the skin surface with 500 μl of PBS and then counted by the drop counting method. Also, to evaluate bacterial survival on skin, 20 μl of bacterial inoculum (2 × 10⁸–2 × 10⁹ cfu/ml) were placed on to the skin, dried for 3 min in a laminar flow cabinet, resuspended with 480 μl of PBS or neutraliser and counted by the drop counting method. For the re-used samples, a control was made to evaluate the remaining bacteria on skin after the first test by rinsing the skin surface with 500 μl of PBS and counting remaining bacteria by the drop counting method.

Because of the limitation of the skin supply, the antibacterial activity of isopropanol 70% was assessed against only three bacterial strains: E. coli K12, S. aureus Oxford and MRSA.

Finally, skin viability was investigated by spectrophotometric measurement of the lactate dehydrogenase (LDH) activity with a diagnostic kit (Test EC 1.1.1.27, catalogue no. DG1340-K, Sigma).

Statistical analyses

Analyses of variance were performed with the Mini-tab® software and were conducted at the 95% confidence interval. Five replicas were performed for

Fig. 1. Ex-vivo protocol.
the suspension and the glass-carrier tests and at least three for the ex-vivo test.

Results

Antibacterial activity of the neutralisers

Table 1 shows the antimicrobial effect of the neutralisers against the bacterial strains investigated. The log_{10} reduction is calculated as log_{10} number of surviving cells (cfu/ml) after exposure to neutralisers – log_{10} number of cells in the control bacterial inoculum.

The neutralisers A, B, C and D did not reduce significantly (p > 0.05) the viable bacterial concentrations of the strains tested.

Efficacy of neutralisers

The neutralising solutions quenched effectively (p > 0.05) the appropriate biocide at the concentration tested (data not shown). As an example, 0.13 log_{10} reduction in bacterial titre was observed when the inoculum was added to a mixture containing both neutraliser D and CHX. This value was not significantly different from the control.

Skin resident flora

Some skin samples showed transient contamination, although the concentration of these bacteria did not exceed 10^2 cfu/ml. When contamination was observed, the concentration of contaminants was taken into account for the calculation of the concentration of the test organisms recovered after the tests.

Bacterial survival on skin

The concentration of surviving cells recovered in PBS, after the drying process on skin (ex-vivo test) or on glass (glass-carrier test), is shown in Fig. 2. These results were compared with that obtained in the suspension test where the bacterial cells were resuspended in neutraliser. There was no significant difference (p > 0.05) in the number of bacterial cells recovered with either protocol for VRE, Ent. faecalis and MRSA. However, S. aureus, S. epidermidis and P. aeruginosa log_{10} concentration were reduced on the glass surface, −0.395 SD 0.48, −0.575 SD 0.853 and −0.721 SD 0.461, respectively. These reductions were significantly (p < 0.05) greater than those observed with the ex-vivo or the suspension tests. The drying process in the ex-vivo test did not have any significant effect on bacterial survival.

Table 1. Antimicrobial activity of the neutralisers

<table>
<thead>
<tr>
<th>Bacterial strains</th>
<th>Neutraliser A</th>
<th>Neutraliser B</th>
<th>Neutraliser C</th>
<th>Neutraliser D</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. aureus</td>
<td>+0.033 (0.115)</td>
<td>+0.126 (0.124)</td>
<td>+0.092 (0.119)</td>
<td>+0.121 (0.087)</td>
</tr>
<tr>
<td>MRSA</td>
<td>+0.177 (0.173)</td>
<td>+0.084 (0.247)</td>
<td>+0.189 (0.153)</td>
<td>+0.049 (0.089)</td>
</tr>
<tr>
<td>Ent. faecalis</td>
<td>+0.181 (0.119)</td>
<td>+0.134 (0.126)</td>
<td>+0.027 (0.191)</td>
<td>+0.035 (0.119)</td>
</tr>
<tr>
<td>VRE</td>
<td>+0.005 (0.095)</td>
<td>+0.026 (0.145)</td>
<td>+0.025 (0.124)</td>
<td>+0.113 (0.174)</td>
</tr>
<tr>
<td>S. epidermidis</td>
<td>+0.167 (0.151)</td>
<td>+0.089 (0.865)</td>
<td>+0.144 (0.119)</td>
<td>+0.225 (0.089)</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>+0.151 (0.382)</td>
<td>+0.160 (0.326)</td>
<td>+0.315 (0.286)</td>
<td>−0.071 (0.039)</td>
</tr>
<tr>
<td>E. coli</td>
<td>+0.098 (0.152)</td>
<td>+0.049 (0.167)</td>
<td>+0.093 (0.096)</td>
<td>+0.147 (0.224)</td>
</tr>
</tbody>
</table>

+, an increase in bacterial titre; −, a reduction in bacterial titre.

Fig. 2. Antibacterial activity due to the drying process on skin (ex-vivo test; □) and on glass (glass-carrier test; □) compared to that in the suspension test (□).
Skin viability

Fig. 3 shows the comparison of LDH activity from two samples of skin. For each sample, one piece was used fresh and another was used after being frozen for 24 h (and then defrosted for 1 h at room temperature before the first measurement of LDH activity).

The LDH activity measured up to 180 h after excision showed that the viability of fresh skin is stable. LDH activity of c. 90 U/L showed that the skin was still viable. When the LDH activity of frozen samples was measured, the results were variable. The LDH activity average was significantly higher (50–500 U/L) with the frozen samples than with the fresh ones.

Effect of the use of fresh or frozen skin samples on the antibacterial activity of the biocides

There was no significant difference (p > 0.05) in the bactericidal activity of biocides tested on fresh or frozen skin, with the exception of PCMX 0.24% tested against E. coli (p < 0.05). Hence, only the results obtained with the fresh samples were taken into account for subsequent analyses of results with E. coli.

Effect of re-utilisation of the skin samples

There was no significant difference (p > 0.05) in antibacterial activity of the biocides tested between the first and the second use of frozen skin samples. When biocides were tested on fresh skin, there was a significant difference (p < 0.05) in results only when povidone iodine 2% was tested against P. aeruginosa. Hence, only the results from the first use of skin were taken into account for subsequent analyses of results for this combination.

Antibacterial activity of biocides against the bacteria investigated after 1-min contact time with the three protocols

When assessed with the suspension test, there was no significant difference in activity between triclosan 0.5% in 70% isopropanol and isopropanol 70% against all bacterial strains (Fig. 4). With the glass-carrier test, the activity of triclosan in isopropanol was higher than that of isopropanol only, with the exception of P. aeruginosa and VRE (Figs. 4a and b). There was also a significant difference in activity between triclosan in isopropanol and isopropanol tested against S. epidermidis with, respectively, 4.949 SD 1.276 and 1.847 SD 0.363 log₁₀ reduction in bacterial concentration (Fig. 4c). With the ex-vivo test, the antibacterial activity of triclosan in isopropanol appeared to be slightly higher than that of isopropanol against S. aureus with, respectively, 1.771 SD 1.142 and 0.511 SD 0.417 log₁₀ reduction in bacterial concentration (Fig. 4d) and against MRSA with, respectively, 1.214 SD 0.806 and 0.314 SD 0.099 log₁₀ reduction in bacterial concentration (Fig. 4e), even though the difference in efficacy was not statistically significant. There was a significant (p <0.05) difference in activity of isopropanol between the two in-vitro tests against VRE and S. epidermidis (Figs. 4b and c). When assessed in the ex-vivo test, isopropanol and triclosan in isopropanol did not show any difference in activity (p > 0.05) against MRSA and S. aureus (Figs. 4d and e).

The antibacterial activity of the biocides tested was always higher with the suspension test except for triclosan, for which the antibacterial activity was similar in the suspension and the glass-carrier test. The antibacterial activity of the biocides was always lower when assessed with the ex-vivo test.

There was a significant difference in biocidal activity

![Fig. 3. Comparison of the LDH activity of two samples of fresh skin which were used as fresh skin (1, –○–; 2, –△–) or after being frozen for 24 h (1a, –○–; 2a, –△–).](image-url)
of all the agents tested against *S. aureus* Oxford, *E. coli* and *Ent. faecalis* between the tests performed (p < 0.05; Fig. 4d, f and g).

With *S. aureus* Oxford (Fig. 4d), biocidal activity tested in suspension was always significantly (p < 0.05) higher than with the ex-vivo test or with the glass-carrier test except for triclosan in isopropanol, for which the activity was higher in the glass-carrier test. The activity of the biocides was significantly higher (p < 0.05) with the glass-carrier test than with the ex-vivo test, for povidone iodine and chlorhexidine for which the activity was not significantly different between these two tests (p > 0.05).

There was no significant difference (p > 0.05) in biocidal activity between the glass-carrier and suspension tests when triclosan in isopropanol was assessed against MRSA (Fig. 4e), and when triclosan in isopropanol or povidone iodine were assessed against VRE (Fig. 4b).

The antibacterial activity of chlorhexidine and povidone iodine was not significantly different (p > 0.05) against *P. aeruginosa* when tested with the glass-carrier or the ex-vivo tests (Fig. 4a). Chlorhexidine showed the greatest activity when tested against *P. aeruginosa* in the ex-vivo test (1.947 SD 1.519 log_{10} reduction in bacterial concentration). Triclosan in isopropanol had the lowest activity (0.758 SD 0.308 log_{10} reduction) against *P. aeruginosa* compared with the other microorganisms investigated.

---

**Fig. 4.** Antibacterial activity of povidone iodine 2% (P), triclosan 0.5% (T), isopropanol 70% (I), PCMX 0.24% (D) and chlorhexidine 2% (C) against (a) *P. aeruginosa*, (b) VRE, (c) *S. epidermidis*, (d) *S. aureus* Oxford, (e) MRSA, (f) *E. coli* K12 and (g) *Ent. faecalis* in the suspension (□), glass-carrier (■) and ex-vivo (●) tests.
Biocides tested against *S. epidermidis* showed a significant difference in activity (p < 0.05) depending on the test performed, with the exception of povidone iodine for which activity was not significantly different (p > 0.05) in the glass-carrier test and the ex-vivo test (Fig. 4c).

With the ex-vivo test, there was no significant difference in the activity (p > 0.05) of the four agents tested against *E. coli* (Fig. 4f).

**Discussion**

It is known that skin samples taken from living or dead persons retain life function [11, 12]. It has been shown that cadaver skin can be energy viable for up to 8 days when stored in Eagle’s Minimum Essential Medium at 4°C [13]. In 1978, clinical experience with frozen auto- or allo-grafts showed no significant difference when compared with the use of freshly harvested auto- or allo-grafts [14]. Fresh skin samples used in the present study came from patients undergoing plastic surgery and were immediately placed in EBSS media and refrigerated. They were used within 3 or 4 days. According to Fig. 3, when the viability of fresh samples was assessed, there was no significant variation in LDH activity within 180 h. It is expected that, at 25°C, the LDH activity of adults will be 125–236 U/L [15]. The LDH activity measured in the fresh samples was lower at 50–90 U/L once stable.

The results with the frozen samples showed a high variability in LDH activity measurement with values rising to 500 U/L. It has been shown that freezing skin for storage can destroy skin viability [13]. Rises in LDH activity are medically associated with many pathological conditions, which might explain such an augmentation with the frozen skin samples. However, this did not seem to have any effect on the tests performed with both skin preparations, fresh or frozen, as there was no significant difference in biocidal activity, with the exception of PCMX tested against *E. coli* K12. However, it has to be noted that demonstration of enzyme activity is not necessarily a proof of cell viability and further tests should be conducted [16].

The antibacterial activity of the biocides tested was always highest when assessed by the suspension test and always lowest when assessed by the ex-vivo test. The bactericidal activity of the agents investigated depended on the test performed and the results were generally significantly different between the various methods.

With the suspension test, most of the biocides achieved a 4–5 log10 reduction in bacterial concentration after only 1 min, with the exception of povidone iodine that achieved 3 log10 reduction with *S. epidermidis* and *E. faecalis* and only a 1 log10 reduction against VRE. Triclosan in isopropanol did not show any significant difference (p > 0.05) in activity when tested in the glass-carrier or suspension tests against MRSA and VRE. However, triclosan in isopropanol showed a significant difference (p < 0.05) in activity between these two in-vitro tests when tested against the other bacterial strains, although its antibacterial activity remained high, i.e., 5 log10 reduction in bacterial concentration after 1 min contact. Most of the time, the antibacterial activity of the other biocides was significantly lower in the glass-carrier test than in the suspension test, i.e., 1–3 log10 difference in bacterial concentration after biocidal challenge.

PCMX 0.24% (diluted Dettol) has been shown to be highly active in vitro (suspension test) with >6 log reduction in viable count within 1 min against *S. aureus*, 5.5 log10 reduction against *Ent. faecium* and 4.9 log10 reduction against *P. aeruginosa* [17]. In the present study, 0.24% PCMX achieved a 4.5–5 log10 reduction in viable count after 1 min contact time against all strains in the suspension test. When tested with a surface test on stainless steel disks 5% Dettol produced, reductions in viable count within 5 min, ranging from 3.5 to 4.5 log10 for *S. aureus*, from 2.9 to >6 log10 for *P. aeruginosa* and from 1.3 to 4.8 log for *Ent. faecium* [18]. The inactivation results on the glass surface (i.e., glass-carrier test) were significantly lower, although in the present study only 1 min contact time was used. Furthermore, the variability in results remained important: 2.065 SD 1.337, 2.699 SD 1.812 and 2.116 SD 0.932 log10 reduction for *S. aureus*, *P. aeruginosa* and *Ent. faecalis* respectively. In one in-vivo study that used artificially contaminated skin, >99% reduction in bacterial count was observed after *S. aureus*, *Ent. faecalis*, *E. coli* and *P. aerugiosa* were challenged with 5% Dettol for 5 min [19]. With the ex-vivo test, the antibacterial activity of PCMX against all strains was generally slightly higher than that of povidone iodine and chlorhexidine (with the exception of *E. coli*), although the difference in activity was not statistically significant. The greatest activity of PCMX was observed when tested against *E. coli* and *S. aureus*, 0.9014 SD 0.5023 and 0.8225 SD 0.8334 log10 reduction in bacterial titre respectively.

From another in-vivo study on hands, 0.5% triclosan in 70% isopropanol (Manusept), was significantly more active against *E. coli* than 60% isopropyl alcohol and 0.5% chlorhexidine in 60% isopropanol [20]. In the present ex-vivo study 0.5% triclosan in 70% isopropa- nol was significantly more active than 70% isopropanol alone and than any of the other three biocides in- vestigated after 1 min contact time. Triclosan has been shown to have poor efficacy for gram-negative bacteria *in vitro* [1] and *in vivo* [21]. In the present study, triclosan in isopropanol had a high antibacterial activity against gram-negative and gram-positive bacteria with the suspension and with the glass-carrier tests, from 4.5
to $5 \log_{10}$ reduction in titre ($4 \log_{10}$ for *P. aeruginosa* in the glass-carrier test) after 1 min contact time. Finally, with the ex-vivo test, triclosan in isopropanol was more active against *gram-positive* bacteria than against both *gram-negative* strains (*E. coli* and *P. aeruginosa*) with, respectively 1.105 SD 0.678 SD 0.678 and 0.7585 SD 0.308 $\log_{10}$ reduction in viable count after 1 min contact time. It is possible that the activity of triclosan was potentiated by the alcohol, as isopropanol 70% showed good efficacy in the glass-carrier and suspension tests. With the ex-vivo and the glass-carrier tests, the antimicrobial activity of triclosan in isopropanol was generally higher than that of isopropanol alone. Isopropanol is known to be an effective antimicrobial agent and is widely used for hard-surface disinfection and skin antisepsis [22]. The isopropanol contained in the triclosan-isopropanol formulation may have a role in its antimicrobial efficacy, as alcohol products added to a low concentration of biocide (triclosan in this case) can enhance the activity of the biocide which remains on the skin after evaporation of the alcohol.

In the in-vitro test results, there was no significant difference in activity (p > 0.05) when the biocides were tested against *S. aureus* or MRSA. In the ex-vivo test, povidone iodine and triclosan in isopropanol did not show any significant (p > 0.05) difference in activity against *S. aureus* and MRSA. These results confirmed other studies in which povidone iodine was shown not to have any significant difference in activity against MRSA or methicillin-sensitive *S. aureus* (MSSA) [23, 24]. Similarly, an investigation of the antibacterial activity of triclosan in a minimum inhibitory concentration method showed no significant difference in activity between MSSA and MRSA [25]. However, it has to be noted that MIC values do not necessarily correlate with bacterial inactivation or minimum bactercidal concentration and in clinical practice, rates of bacterial inactivation are probably more relevant than MIC values [26].

According to a recent in-vivo study, triclosan 1% (Novaderm R formulation) was shown to remove effectively (p < 0.05) MRSA from the hands of staff volunteers in an acute surgical ward after 30 s contact, whereas chlorhexidine gluconate 4% failed to do so [21]. In the present study, triclosan 0.5% in isopropanol was significantly more effective (p < 0.05) against MRSA than chlorhexidine 2% in the ex-vivo test. Other in-vivo studies have reported successful control or elimination of MRSA after the introduction of triclosan topical antimicrobial formulations [27–30].

Although the antibacterial activity of chlorhexidine and PCMX were statistically significantly (p < 0.05) higher against *S. aureus* than against MRSA, differences remain marginal, with 0.782 SD 0.496 $\log_{10}$ reduction in *S. aureus* concentration and 0.504 SD 0.301 $\log_{10}$ reduction in MRSA concentration with chlorhexidine, and 0.822 SD 0.833 $\log_{10}$ reduction in *S. aureus* concentration and 0.303 SD 0.253 $\log_{10}$ reduction in MRSA concentration with PCMX. Similarly, it was shown in an in-vitro study that chlorhexidine was more active against *S. aureus* than against MRSA [31]. However, Cookson et al. [32] found no difference in the antimicrobial activity of chlorhexidine 4% between MRSA and MSSA when tested with an in-vivo protocol. Furthermore, some in-vitro studies (MIC and time-kill studies) have shown no difference in antibacterial activity of the biguanide between *S. aureus* and MRSA [33] or when PCMX 1% was tested [23].

The bactericidal activity of the four biocides tested was not significantly different (p > 0.05) between VRE and *E. faecalis* in the glass-carrier test. With the suspension test, although the activity of chlorhexidine 2% and triclosan 0.5% in isopropanol was the same for these two micro-organisms, the activities of povidone iodine 2% and PCMX 5% were marginally higher (p < 0.05) against *Ent. faecalis* than against VRE. In contrast, in the ex-vivo test, povidone iodine 2% antibacterial activity was statistically significantly higher (p < 0.05) against VRE than against *Ent. faecalis*, although results were very similar with, respectively, 0.699 SD 0.31 and 0.427 SD 0.361 $\log_{10}$ reduction in bacterial concentration. Whether such a small difference in activity of biocides against VRE and vancomycin-sensitive enterococci (VSE) is significant in situ remains to be determined. Previous in-vitro studies have also failed to demonstrate a difference in disinfectant susceptibility between VRE and VSE [26, 33–35].

Another study showed that chlorhexidine 4% and povidone iodine 7.5% were very effective (i.e., 4 $\log_{10}$ reduction after 30 s contact time) against VRE inoculated on to the skin [36]. This result was much higher than those obtained with the ex-vivo test in the present study. A possible explanation is that in the ex-vivo study, fingertips were rubbed against each other, thus possibly physically removing some micro-organisms from the skin surface, whereas with the ex-vivo test, there was no rubbing effect.

This study showed that the antibacterial activity of four biocides commonly used as handwash products depended upon the procedures used (i.e., in-vitro or ex-vivo protocol). To date, handwash formulations with antiseptic properties are well documented and investigated in the literature [1], usually on the basis of the results of in-vitro tests. The suspension test protocol has been shown to give an overestimation of the antibacterial activity of biocides investigated [5]. The glass-carrier test is not always reliable because of the significant loss of bacterial cells from the drying step. The ex-vivo test provides a close imitation of human skin behaviour, although there is no longer any vascularisation or glands going to the dermis or basal layers. However, this should be of little significance for the testing of antiseptics, because the *stratum corneum*...
is essentially a non-living tissue. This protocol is easy to use and allows the testing of pathogenic microorganisms such as MRSA and VRE, it is becoming increasingly necessary to be able to assess biocidal activity of an antiseptic directly on skin. This comment is particularly pertinent since the results showed that there was a significant difference in the activity of biocides depending on the test used. Finally, this study confirmed that the ex vivo method should be useful for manufacturers of antimicrobial agents and regulatory agencies to ensure that commercially available formulations meet their claims when used according to manufacturers’ instructions [6].

We thank Reckitt & Colman for the financial support and Miss Ying Hui Teo for providing the skin samples.

References


